{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:56:34Z","timestamp":1793656594565,"version":"4.5.1"},"reference-count":195,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e33091","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T20:50:16Z","timestamp":1718398216000},"page":"e33091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells"],"prefix":"10.1016","volume":"10","author":[{"given":"Kuntal","family":"Bhowmick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"von Suskil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar S.","family":"Al-Odat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weam Othman","family":"Elbezanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subash C.","family":"Jonnalagadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulin","family":"Budak-Alpdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-2929","authenticated-orcid":false,"given":"Manoj K.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.heliyon.2024.e33091_bib1","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20140692","article-title":"Fibroblast heterogeneity in the cancer wound","volume":"211","author":"Ohlund","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.heliyon.2024.e33091_bib2","series-title":"Cancer Facts & Figures 2024. 2024, Atlanta","author":"Society","year":"2024"},{"key":"10.1016\/j.heliyon.2024.e33091_bib3","doi-asserted-by":"crossref","first-page":"973836","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche","volume":"12","author":"Solimando","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33091_bib4","first-page":"467","article-title":"MicroRNA therapeutics: the next magic bullet? Mini rev med chem","volume":"15","author":"Simonson","year":"2015"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33091_bib5","first-page":"1046","article-title":"Multiple myeloma. N engl J med","volume":"364","author":"Palumbo","year":"2011"},{"key":"10.1016\/j.heliyon.2024.e33091_bib6","first-page":"13","article-title":"The role of tumor microenvironment in multiple myeloma development and progression. Cancers","volume":"2","author":"Garcia-Ortiz","year":"2021","journal-title":"Basel"},{"key":"10.1016\/j.heliyon.2024.e33091_bib7","doi-asserted-by":"crossref","first-page":"1367875","DOI":"10.3389\/fimmu.2024.1367875","article-title":"Endothelial cells in tumor microenvironment: insights and perspectives","volume":"15","author":"Leone","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e33091_bib8","doi-asserted-by":"crossref","first-page":"599098","DOI":"10.3389\/fonc.2020.599098","article-title":"Actors on the scene: immune cells in the myeloma niche","volume":"10","author":"Leone","year":"2020","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33091_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat. Immunol."},{"issue":"37","key":"10.1016\/j.heliyon.2024.e33091_bib10","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: emerging new players","volume":"7","author":"Di Marzo","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33091_bib11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33091_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-11-2212","article-title":"Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects","volume":"18","author":"Reagan","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33091_bib13","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.leu.2404466","article-title":"Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma","volume":"21","author":"Arnulf","year":"2007","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33091_bib15","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3109\/10428194.2011.576791","article-title":"Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression","volume":"52","author":"Hao","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33091_bib16","first-page":"1138","article-title":"[Biological properties of mesenchymal stem cells derived from bone marrow of patients with multiple myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi","volume":"14","author":"Zhu","year":"2006"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00005-008-0022-5","article-title":"Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells","volume":"56","author":"Zdzisinska","year":"2008","journal-title":"Arch. Immunol. Ther. Exp."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33091_bib18","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V84.7.2269.2269","article-title":"Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures","volume":"84","author":"Lokhorst","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e33091_bib19","first-page":"13","article-title":"The immune microenvironment in multiple myeloma: friend or foe?","volume":"4","author":"Lopes","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e33091_bib20","doi-asserted-by":"crossref","first-page":"1102471","DOI":"10.3389\/fimmu.2022.1102471","article-title":"The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e33091_bib21","first-page":"23","article-title":"The role of T cell immunity in monoclonal gammopathy and multiple myeloma: from immunopathogenesis to novel therapeutic approaches","volume":"9","author":"Lagreca","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e33091_bib22","doi-asserted-by":"crossref","first-page":"1359084","DOI":"10.3389\/fcell.2024.1359084","article-title":"Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma","volume":"12","author":"Zhang","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00109-015-1345-4","article-title":"Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities","volume":"94","author":"Shay","year":"2016","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10555-011-9268-1","article-title":"Myeloid cell diversification and complexity: an old concept with new turns in oncology","volume":"30","author":"Chioda","year":"2011","journal-title":"Cancer Metastasis Rev."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib27","first-page":"634","article-title":"Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer cell","volume":"33","author":"Nakamura","year":"2018"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33091_bib28","first-page":"9159","article-title":"Adipokines, adiposity, and bone marrow adipocytes: dangerous accomplices in multiple myeloma. J Cell Physiol","volume":"233","author":"Morris","year":"2018"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33091_bib29","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e33091_bib30","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.7150\/jca.30102","article-title":"High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens","volume":"10","author":"Wang","year":"2019","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib31","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2141.2012.09154.x","article-title":"Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells","volume":"158","author":"Kim","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e33091_bib32","first-page":"183602","article-title":"Multiple myeloma macrophages: pivotal players in the tumor microenvironment","volume":"2013","author":"Berardi","year":"2013","journal-title":"JAMA Oncol."},{"issue":"17","key":"10.1016\/j.heliyon.2024.e33091_bib33","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e33091_bib34","first-page":"21","article-title":"Bone marrow stromal cells-induced drug resistance in multiple myeloma","volume":"2","author":"Ria","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e33091_bib35","first-page":"5796","article-title":"A HGF\/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target. Clinical cancer research","volume":"20","author":"Ferrucci","year":"2014"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33091_bib36","first-page":"1438","article-title":"A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost","volume":"92","author":"Ria","year":"2004"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33091_bib37","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood-2003-04-1338","article-title":"Endothelial cells in the bone marrow of patients with multiple myeloma","volume":"102","author":"Vacca","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib38","first-page":"847","article-title":"HIF-1\u03b1 of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clinical cancer research","volume":"20","author":"Ria","year":"2014"},{"issue":"23","key":"10.1016\/j.heliyon.2024.e33091_bib39","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood.V126.23.3026.3026","article-title":"Final analysis of overall survival from the phase 3 panorama 1 trial of panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma","volume":"126","author":"San-Miguel","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e33091_bib40","first-page":"2331","article-title":"Panorama 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood","volume":"122","author":"Richardson","year":"2013"},{"key":"10.1016\/j.heliyon.2024.e33091_bib41","doi-asserted-by":"crossref","first-page":"1193978","DOI":"10.3389\/fonc.2023.1193978","article-title":"Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets","volume":"13","author":"Ding","year":"2023","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib42","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/leu.2013.254","article-title":"Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies","volume":"28","author":"Frassanito","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib43","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/leu.2015.289","article-title":"Halting pro-survival autophagy by TGFbeta inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients","volume":"30","author":"Frassanito","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e33091_bib44","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3389\/fimmu.2019.01835","article-title":"The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment","volume":"10","author":"Monteran","year":"2019","journal-title":"Front. Immunol."},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2024.e33091_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123277","article-title":"Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma","volume":"134","author":"Sakemura","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib46","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/0008-5472.CAN-20-1088","article-title":"Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype","volume":"81","author":"Fairfield","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33091_bib47","doi-asserted-by":"crossref","first-page":"897862","DOI":"10.3389\/fimmu.2022.897862","article-title":"Multiple myeloma metabolism - a treasure trove of therapeutic targets?","volume":"13","author":"Roman-Trufero","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e33091_bib48","first-page":"15","article-title":"Unlocking drug resistance in multiple myeloma: adipocytes as modulators of treatment response","volume":"17","author":"Ochiai","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e33091_bib49","first-page":"895045","article-title":"Novel adipokines and bone metabolism","volume":"2013","author":"Liu","year":"2013","journal-title":"Internet J. Endocrinol."},{"key":"10.1016\/j.heliyon.2024.e33091_bib50","first-page":"109","article-title":"Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study","volume":"5","author":"Chang","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"52","key":"10.1016\/j.heliyon.2024.e33091_bib51","doi-asserted-by":"crossref","first-page":"86075","DOI":"10.18632\/oncotarget.13342","article-title":"Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"issue":"33","key":"10.1016\/j.heliyon.2024.e33091_bib52","doi-asserted-by":"crossref","first-page":"34329","DOI":"10.18632\/oncotarget.6020","article-title":"Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation","volume":"6","author":"Liu","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33091_bib53","first-page":"3054","article-title":"Adipocyte-lineage cells support growth and dissemination of multiple myeloma in bone. Am J pathol","volume":"186","author":"Trotter","year":"2016"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10173","article-title":"Multiple myeloma and fatty acid metabolism","volume":"3","author":"Masarwi","year":"2019","journal-title":"JBMR Plus"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib55","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33091_bib56","first-page":"131","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood","volume":"142","author":"Bird","year":"2023"},{"issue":"38","key":"10.1016\/j.heliyon.2024.e33091_bib57","doi-asserted-by":"crossref","first-page":"40496","DOI":"10.18632\/oncotarget.5800","article-title":"Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?","volume":"6","author":"Franqui-Machin","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33091_bib58","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7123","key":"10.1016\/j.heliyon.2024.e33091_bib59","first-page":"106","article-title":"A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature","volume":"445","author":"O'Brien","year":"2007"},{"issue":"7015","key":"10.1016\/j.heliyon.2024.e33091_bib60","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib61","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrc.2017.125","article-title":"Targeting minimal residual disease: a path to cure?","volume":"18","author":"Luskin","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4252\/wjsc.v7.i1.84","article-title":"Identify multiple myeloma stem cells: utopia?","volume":"7","author":"Saltarella","year":"2015","journal-title":"World J. Stem Cell."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33091_bib63","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41375-018-0061-9","article-title":"Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?","volume":"32","author":"Xu","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e33091_bib64","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1080\/10428190701593644","article-title":"Mesenchymal stem cell abnormalities in patients with multiple myeloma","volume":"48","author":"Garderet","year":"2007","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33091_bib65","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/1097-0142(20010401)91:7<1219::AID-CNCR1122>3.0.CO;2-1","article-title":"Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients","volume":"91","author":"Wallace","year":"2001","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.heliyon.2024.e33091_bib66","doi-asserted-by":"crossref","first-page":"35466","DOI":"10.18632\/oncotarget.8154","article-title":"Multiple myeloma cancer stem cells","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib67","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","article-title":"The bone-marrow niche in MDS and MGUS: implications for AML and MM","volume":"15","author":"Ghobrial","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33091_bib68","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1089\/ars.2012.5019","article-title":"Hypoxia and metabolic properties of hematopoietic stem cells","volume":"20","author":"Zhang","year":"2014","journal-title":"Antioxidants Redox Signal."},{"key":"10.1016\/j.heliyon.2024.e33091_bib69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coph.2016.02.013","article-title":"New approaches to targeting the bone marrow microenvironment in multiple myeloma","volume":"28","author":"Gooding","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33091_bib70","first-page":"444","article-title":"HIF-1alpha inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment. Exp Cell Res","volume":"328","author":"Borsi","year":"2014"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib71","first-page":"72","article-title":"Overexpression of HIF-1alpha contributes to melphalan resistance in multiple myeloma cells by activation of ERK1\/2, Akt, and NF-kappaB. Lab Invest","volume":"99","author":"Tsubaki","year":"2019"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib72","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2015.133736","article-title":"The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1alpha inhibition in myeloma cells","volume":"101","author":"Storti","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2024.e33091_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.82","article-title":"Hypoxia promotes stem cell-like phenotype in multiple myeloma cells","volume":"4","author":"Muz","year":"2014","journal-title":"Blood Cancer J."},{"issue":"4867","key":"10.1016\/j.heliyon.2024.e33091_bib74","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.3136546","article-title":"Cloning and expression of the human interleukin-6 (BSF-2\/IFN beta 2) receptor","volume":"241","author":"Yamasaki","year":"1988","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33091_bib75","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.18632\/oncotarget.1736","article-title":"Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma","volume":"5","author":"Borsi","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e33091_bib76","first-page":"11","article-title":"STAT3: a promising therapeutic target in multiple myeloma","volume":"5","author":"Chong","year":"2019","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33091_bib77","first-page":"736","article-title":"Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer","volume":"14","author":"Yu","year":"2014"},{"issue":"19","key":"10.1016\/j.heliyon.2024.e33091_bib78","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1158\/0008-5472.CAN-10-0736","article-title":"Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells","volume":"70","author":"Herrmann","year":"2010","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e33091_bib79","doi-asserted-by":"crossref","first-page":"9599","DOI":"10.1158\/0008-5472.CAN-10-1293","article-title":"Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects","volume":"70","author":"Kujawski","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33091_bib80","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0955-0674(97)80068-3","article-title":"AP-1 function and regulation","volume":"9","author":"Karin","year":"1997","journal-title":"Curr. Opin. Cell Biol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33091_bib81","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2016.358","article-title":"The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment","volume":"31","author":"Fan","year":"2017","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e33091_bib82","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","article-title":"ABT-737 is highly effective against molecular subgroups of multiple myeloma","volume":"118","author":"Bodet","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e33091_bib83","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33091_bib84","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17474086.2018.1548931","article-title":"Venetoclax for the treatment of multiple myeloma","volume":"11","author":"Vaxman","year":"2018","journal-title":"Expert Rev. Hematol."},{"issue":"25","key":"10.1016\/j.heliyon.2024.e33091_bib85","first-page":"2919","article-title":"MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood","volume":"128","author":"Qiang","year":"2016"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33091_bib86","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1158\/0008-5472.CAN-05-2154","article-title":"Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human","volume":"66","author":"Morito","year":"2006","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33091_bib87","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/PAS.0b013e318054dbcf","article-title":"c-Maf expression in angioimmunoblastic T-cell lymphoma","volume":"31","author":"Murakami","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"30","key":"10.1016\/j.heliyon.2024.e33091_bib88","doi-asserted-by":"crossref","first-page":"48732","DOI":"10.18632\/oncotarget.8982","article-title":"The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential","volume":"7","author":"Bieghs","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33091_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051512","article-title":"Old and young actors playing novel roles in the drama of multiple myeloma bone marrow microenvironment dependent drug resistance","volume":"19","author":"Manni","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2024.e33091_bib90","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428190009060320","article-title":"Integrin-mediated drug resistance in multiple myeloma","volume":"38","author":"Damiano","year":"2000","journal-title":"Leuk. Lymphoma"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e33091_bib91","doi-asserted-by":"crossref","first-page":"10241","DOI":"10.1016\/S0021-9258(18)99215-X","article-title":"Functional evidence for three distinct and independently inhibitable adhesion activities mediated by the human integrin VLA-4. Correlation with distinct alpha 4 epitopes","volume":"266","author":"Pulido","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e33091_bib92","doi-asserted-by":"crossref","first-page":"100253","DOI":"10.1016\/j.jbo.2019.100253","article-title":"The role of CXCR4 in multiple myeloma: cells' journey from bone marrow to beyond","volume":"17","author":"Ullah","year":"2019","journal-title":"J Bone Oncol"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib93","first-page":"118","article-title":"SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep","volume":"9","author":"Roccaro","year":"2014"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib94","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.canlet.2015.11.028","article-title":"Targeting SDF-1 in multiple myeloma tumor microenvironment","volume":"380","author":"Bouyssou","year":"2016","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33091_bib95","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33091_bib96","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.clml.2018.03.007","article-title":"Various signaling pathways in multiple myeloma cells and effects of treatment on these pathways","volume":"18","author":"Dehghanifard","year":"2018","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e33091_bib97","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.0305855101","article-title":"Illegitimate WNT signaling promotes proliferation of multiple myeloma cells","volume":"101","author":"Derksen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33091_bib98","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1158\/1535-7163.MCT-06-0684","article-title":"Wnt3\/RhoA\/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism","volume":"6","author":"Kobune","year":"2007","journal-title":"Mol. Cancer Therapeut."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33091_bib99","first-page":"1825","article-title":"The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood","volume":"104","author":"Schmidmaier","year":"2004"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib100","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.semcancer.2010.04.003","article-title":"Adhesion molecules\u2013The lifelines of multiple myeloma cells","volume":"20","author":"Katz","year":"2010","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33091_bib101","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"issue":"38","key":"10.1016\/j.heliyon.2024.e33091_bib102","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1038\/sj.onc.1203782","article-title":"Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)","volume":"19","author":"Hazlehurst","year":"2000","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33091_bib103","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/onc.2008.385","article-title":"Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma","volume":"28","author":"Noborio-Hatano","year":"2009","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib104","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2008.07217.x","article-title":"HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma","volume":"142","author":"Nimmanapalli","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"1\u20132","key":"10.1016\/j.heliyon.2024.e33091_bib105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11010-013-1856-7","article-title":"Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells","volume":"386","author":"Fei","year":"2014","journal-title":"Mol. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33091_bib106","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1158\/1535-7163.MCT-09-0645","article-title":"The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance","volume":"9","author":"Meinel","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33091_bib107","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood.V99.11.4079","article-title":"Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e33091_bib108","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/sj.onc.1206315","article-title":"Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB\/p50) in myeloma cells","volume":"22","author":"Landowski","year":"2003","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33091_bib109","first-page":"3704","article-title":"Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells. Blood","volume":"85","author":"Huang","year":"1995"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33091_bib110","first-page":"3503","article-title":"Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood","volume":"103","author":"Nefedova","year":"2004"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib111","first-page":"717","article-title":"Notch increased vitronection adhesion protects myeloma cells from drug induced apoptosis. Biochemical and Biophysical Research Communications","volume":"467","author":"Ding","year":"2015"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33091_bib112","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","article-title":"Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion","volume":"82","author":"Uchiyama","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e33091_bib113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2015.03.002","article-title":"Shaping of the tumor microenvironment: stromal cells and vessels","volume":"34","author":"Blonska","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib114","article-title":"The \"vesicular intelligence\" strategy of blood cancers. Genes (basel)","volume":"12","author":"Forte","year":"2021"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33091_bib115","article-title":"Good cop, bad cop: profiling the immune landscape in multiple myeloma. Biomolecules","volume":"13","author":"Sharma","year":"2023"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33091_bib116","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.addr.2011.04.002","article-title":"Role of tumor vascular architecture in drug delivery","volume":"63","author":"Narang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib117","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33091_bib118","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/sj.bjc.6601613","article-title":"Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model","volume":"90","author":"Menu","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33091_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115707","article-title":"Bruton's tyrosine kinase targeting in multiple myeloma","volume":"22","author":"Von Suskil","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33091_bib120","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ajh.23433","article-title":"Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease","volume":"88","author":"Bam","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib121","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib122","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib123","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","article-title":"Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib124","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing","volume":"26","author":"de Gorter","year":"2007","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33091_bib125","first-page":"4139","article-title":"BTK induces CAM-DR through regulation of CXCR4 degradation in multiple myeloma","volume":"11","author":"Wang","year":"2019","journal-title":"Am J Transl Res"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e33091_bib126","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1080\/15384101.2014.998067","article-title":"Ibrutinib inhibits BTK-driven NF-kappaB p65 activity to overcome bortezomib-resistance in multiple myeloma","volume":"14","author":"Murray","year":"2015","journal-title":"Cell Cycle"},{"issue":"34","key":"10.1016\/j.heliyon.2024.e33091_bib127","doi-asserted-by":"crossref","first-page":"56858","DOI":"10.18632\/oncotarget.18096","article-title":"BTK suppresses myeloma cellular senescence through activating AKT\/P27\/Rb signaling","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e33091_bib128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.exphem.2017.06.003","article-title":"A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis","volume":"53","author":"Pandey","year":"2017","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.heliyon.2024.e33091_bib129","doi-asserted-by":"crossref","first-page":"894535","DOI":"10.3389\/fphar.2022.894535","article-title":"Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells","volume":"13","author":"Elbezanti","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib130","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12185-016-2048-5","article-title":"Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma","volume":"104","author":"Furukawa","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib131","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-017-0492-1","article-title":"Role of epigenetics-microRNA axis in drug resistance of multiple myeloma","volume":"10","author":"Rastgoo","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33091_bib132","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.exphem.2017.12.012","article-title":"Scriptaid inhibits cell survival, cell cycle, and promotes apoptosis in multiple myeloma via epigenetic regulation of p21","volume":"60","author":"Yao","year":"2018","journal-title":"Exp. Hematol."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33091_bib133","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14740338.2019.1615051","article-title":"A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma","volume":"18","author":"Cengiz Seval","year":"2019","journal-title":"Expet Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib134","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13148-021-01160-z","article-title":"Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma","volume":"13","author":"Herviou","year":"2021","journal-title":"Clin. Epigenet."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33091_bib135","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/med.21972","article-title":"Histone deacetylase-based dual targeted inhibition in multiple myeloma","volume":"43","author":"Ferro","year":"2023","journal-title":"Med. Res. Rev."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib136","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13046-021-01909-7","article-title":"Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma","volume":"40","author":"Hirano","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e33091_bib137","doi-asserted-by":"crossref","first-page":"971070","DOI":"10.3389\/fphar.2022.971070","article-title":"Comprehensive elaboration of circular RNA in multiple myeloma","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33091_bib138","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2050-7771-2-10","article-title":"Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment","volume":"2","author":"Abdi","year":"2014","journal-title":"Biomark. Res."},{"issue":"35","key":"10.1016\/j.heliyon.2024.e33091_bib139","doi-asserted-by":"crossref","first-page":"38270","DOI":"10.18632\/oncotarget.5681","article-title":"MicroRNA-15a\/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e33091_bib140","doi-asserted-by":"crossref","first-page":"14993","DOI":"10.18632\/oncotarget.3802","article-title":"MicroRNA-451 regulates stemness of side population cells via PI3K\/Akt\/mTOR signaling pathway in multiple myeloma","volume":"6","author":"Du","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e33091_bib141","doi-asserted-by":"crossref","first-page":"608815","DOI":"10.3389\/fonc.2020.608815","article-title":"Exosomes in the pathogenesis and treatment of multiple myeloma in the context of the bone marrow microenvironment","volume":"10","author":"Chen","year":"2020","journal-title":"Front. Oncol."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e33091_bib142","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood.2021014749","article-title":"Exosomes in multiple myeloma: from bench to bedside","volume":"140","author":"Menu","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib143","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01683-w","article-title":"Circulating biosignatures in multiple myeloma and their role in multidrug resistance","volume":"22","author":"Krishnan","year":"2023","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33091_bib144","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cbin.11540","article-title":"Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib","volume":"45","author":"Tang","year":"2021","journal-title":"Cell Biol. Int."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib145","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib146","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/bjh.19049","article-title":"Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma","volume":"203","author":"Mizuhara","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"41","key":"10.1016\/j.heliyon.2024.e33091_bib147","doi-asserted-by":"crossref","first-page":"43992","DOI":"10.18632\/oncotarget.6083","article-title":"The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"25","key":"10.1016\/j.heliyon.2024.e33091_bib148","doi-asserted-by":"crossref","first-page":"38927","DOI":"10.18632\/oncotarget.7792","article-title":"Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33091_bib149","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113503","article-title":"NRF2 is one of the players involved in bone marrow mediated drug resistance in multiple myeloma","volume":"19","author":"Yen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33091_bib150","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbamcr.2008.01.002","article-title":"NF-kappaB\/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK","volume":"1783","author":"Liu","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33091_bib151","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.bcp.2008.07.017","article-title":"Activation of Nrf2-antioxidant signaling attenuates NFkappaB-inflammatory response and elicits apoptosis","volume":"76","author":"Li","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib152","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.3892\/mmr.2017.7205","article-title":"Curcumin prevents reperfusion injury following ischemic stroke in rats via inhibition of NFkappaB, ICAM-1, MMP-9 and caspase-3 expression","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.heliyon.2024.e33091_bib153","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.toxlet.2018.01.020","article-title":"Protection by dimethyl fumarate against diabetic cardiomyopathy in type 1 diabetic mice likely via activation of nuclear factor erythroid-2 related factor 2","volume":"287","author":"Hu","year":"2018","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib154","doi-asserted-by":"crossref","first-page":"72","DOI":"10.7150\/ijbs.13188","article-title":"Isovitexin exerts anti-inflammatory and anti-oxidant activities on lipopolysaccharide-induced acute lung injury by inhibiting MAPK and NF-kappaB and activating HO-1\/Nrf2 pathways","volume":"12","author":"Lv","year":"2016","journal-title":"Int. J. Biol. Sci."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e33091_bib155","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3287.3287","article-title":"Dual activation of NRF2 in multiple myeloma and bone marrow mesenchymal stromal cells regulates chemotherapy resistance","volume":"128","author":"Sun","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e33091_bib156","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/164_2017_10","article-title":"Mechanisms of resistance in multiple myeloma","volume":"249","author":"Papadas","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e33091_bib157","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1476-4598-9-176","article-title":"Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells","volume":"9","author":"Markovina","year":"2010","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33091_bib158","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33091_bib159","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1172\/JCI88152","article-title":"Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance","volume":"126","author":"Alonso","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e33091_bib160","doi-asserted-by":"crossref","first-page":"101100","DOI":"10.1016\/j.blre.2023.101100","article-title":"Proteasome inhibition in combination with immunotherapies: state-of-the-Art in multiple myeloma","volume":"61","author":"Kegyes","year":"2023","journal-title":"Blood Rev."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33091_bib161","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/CCO.0000000000000677","article-title":"Immunotherapy in multiple myeloma: when, where, and for who?","volume":"32","author":"Verkleij","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e33091_bib162","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33091_bib163","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.tips.2023.05.006","article-title":"Overcoming proteasome inhibitor resistance in the immunotherapy era","volume":"44","author":"Patino-Escobar","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.heliyon.2024.e33091_bib164","doi-asserted-by":"crossref","first-page":"624661","DOI":"10.3389\/fonc.2020.624661","article-title":"Daratumumab for the management of newly diagnosed and relapsed\/refractory multiple myeloma: current and emerging treatments","volume":"10","author":"Offidani","year":"2020","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e33091_bib165","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33091_bib166","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/13543784.2021.1955103","article-title":"Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options","volume":"30","author":"Le Calvez","year":"2021","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.heliyon.2024.e33091_bib167","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3389\/fimmu.2019.01744","article-title":"Glucocorticoids-all-rounders tackling the versatile players of the immune system","volume":"10","author":"Strehl","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib168","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2012.04.010","article-title":"Bortezomib combination therapy in multiple myeloma","volume":"49","author":"Kapoor","year":"2012","journal-title":"Semin. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib169","first-page":"213","article-title":"A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood","volume":"79","author":"Moalli","year":"1992"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33091_bib170","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1365-2141.2008.07549.x","article-title":"Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1)","volume":"144","author":"Sanchez-Vega","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e33091_bib171","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1158\/1078-0432.CCR-08-3336","article-title":"Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma","volume":"15","author":"Nojima","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib172","first-page":"489","article-title":"Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k\/Akt\/NF-kappaB pathways in human multiple myeloma cells","volume":"22","author":"Yang","year":"2008","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib173","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33091_bib174","first-page":"321","volume":"17","author":"Weidle","year":"2020","journal-title":"Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models. Cancer Genomics Proteomics"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib175","first-page":"224","article-title":"Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood","volume":"100","author":"Spanswick","year":"2002"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33091_bib176","first-page":"698","article-title":"The FA\/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood","volume":"106","author":"Chen","year":"2005"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e33091_bib177","article-title":"MAGE-A mediate resistance to chemotherapy in multiple myeloma through regulation of bcl-2 proteins. Blood","volume":"128","author":"Cho","year":"2016"},{"issue":"6168","key":"10.1016\/j.heliyon.2024.e33091_bib178","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"6168","key":"10.1016\/j.heliyon.2024.e33091_bib179","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.heliyon.2024.e33091_bib180","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33091_bib181","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes","volume":"128","author":"Kortum","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e33091_bib182","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12885-016-2331-0","article-title":"Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival","volume":"16","author":"Xu","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.heliyon.2024.e33091_bib183","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e33091_bib185","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1182\/blood-2006-12-061812","article-title":"CD38\/CD19: a lipid raft-dependent signaling complex in human B cells","volume":"109","author":"Deaglio","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib186","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33091_bib187","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol. Rev."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e33091_bib188","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33091_bib189","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2015.139667","article-title":"Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance","volume":"101","author":"de Haart","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33091_bib190","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030415","article-title":"Past, present, and a glance into the future of multiple myeloma treatment","volume":"16","author":"Elbezanti","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33091_bib191","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","article-title":"B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Expet Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33091_bib192","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"Supplement 1","key":"10.1016\/j.heliyon.2024.e33091_bib193","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-190583","article-title":"A real-world comparison of idecabtagene vicleucel and ciltacabtagene autoleucel CAR-T therapy: a single center experience for relapsed\/refractory multiple myeloma","volume":"142","author":"Gill","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33091_bib194","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33091_bib195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024091229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024091229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T20:44:48Z","timestamp":1790541888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024091229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":195,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024091229"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33091","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e33091"}}